If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.



Von Eschenbach picked to lead FDA

March 20, 2006 | A version of this story appeared in Volume 84, Issue 12

Credit: Photo By Glogau Photography
von Eschenbach
Credit: Photo By Glogau Photography
von Eschenbach

President George W. Bush has nominated Andrew C. von Eschenbach as FDA commissioner. Presently serving as acting FDA chief and as director of the National Cancer Institute, von Eschenbach, 64, is a urology surgeon who served as director of the M. D. Anderson Cancer Center in Houston before moving to NCI in 2002. If confirmed by the Senate, he will give up his NCI post. He would succeed Lester M. Crawford, who suddenly resigned in September 2005 after serving as commissioner for less than three months. The confirmation is expected to be problematic as two senators, Hillary Rodham Clinton (D-N.Y.) and Patty Murray (D-Wash.), have already said they will prevent a vote on von Eschenbach until they receive assurance that FDA will make a final decision on over-the-counter sales of the emergency contraceptive known as Plan B. An FDA scientific advisory board recommended that Plan B be sold over-the-counter, but FDA has been delaying a decision on the case for years. Critics have charged the Bush Administration with letting its political ideology overrule scientific conclusions. Despite this controversy, Sen. Mike Enzi (R-Wyo.), chairman of the Health, Education, Labor & Pension Committee, said he will hold hearings on von Eschenbach's nomination soon.


This article has been sent to the following recipient:

Chemistry matters. Join us to get the news you need.